Halozyme Therapeutics, Inc.

CEO Helen Torley has overseen the pivot to a durable royalty platform and consistent execution with partners, evidenced by multiple approvals and raised guidance. Communications are clear, guidance has been conservative then raised, and capital returns have been sizable.

Management is proactively defending IP, including a 2025 lawsuit related to Keytruda SC, and broadening the technology stack via M&A.